Literature DB >> 12401722

Relationship of phospholipid transfer protein activity to HDL and apolipoprotein B-containing lipoproteins in subjects with and without type 1 diabetes.

Helen M Colhoun1, Marja-Riitta Taskinen, James D Otvos, Paul Van Den Berg, John O'Connor, Arie Van Tol.   

Abstract

Patients with type 1 diabetes have greatly increased phospholipid transfer protein (PLTP) activity and have an altered HDL subclass distribution. In 195 patients with type 1 diabetes and in 194 men and women aged 30-55 years, we examined the relationship of PLTP activity to HDL and examined whether PLTP activity contributes to differences in HDL found in type 1 diabetes. PLTP activity was measured using an exogenous substrate assay. Average HDL particle size and HDL subclasses were measured using nuclear magnetic resonance spectroscopy. Apolipoprotein AI (apoAI) and apoAII were measured by immunoturbidimetry. The amount of apoAI present in LpAI was measured using a differential electroimmunoassay, and the amount of apoAI in LpAIAII was inferred from the apoAI and LpAI data. Higher PLTP activity was associated with more large HDL (P < 0.001) and less small HDL (P < 0.01), more apoAI and apoAII (both at P < 0.001), and more apoAI in both LpAI and LpAIAII (P = 0.02 and P < 0.001, respectively). These associations were independent of other lipids and enzyme activities. Adjusting for PLTP activity halved the difference between subjects with and without diabetes in apoA1 (from 10.1 mg/dl higher in subjects with diabetes to 4.6 mg/dl higher) and large HDL (2.4 micro mol/l higher to 1.2 micro mol/l higher) and reduced the difference in HDL size (from 0.31 nm higher to 0.26 nm higher). PLTP activity was also positively associated with apoB, total VLDL and LDL particle number, and IDL level in subjects with diabetes. These data support the idea that PLTP is a major factor in HDL conversion and remodeling in humans and that higher PLTP activity makes an important contribution to the higher apoAI levels and altered HDL subclass distribution in type 1 diabetes. They also support a role for PLTP in the metabolism of apoB-containing lipoproteins.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12401722     DOI: 10.2337/diabetes.51.11.3300

Source DB:  PubMed          Journal:  Diabetes        ISSN: 0012-1797            Impact factor:   9.461


  20 in total

Review 1.  Role of plasma phospholipid transfer protein in lipid and lipoprotein metabolism.

Authors:  John J Albers; Simona Vuletic; Marian C Cheung
Journal:  Biochim Biophys Acta       Date:  2011-06-28

2.  Liver phospholipid transfer protein (PLTP) expression with a PLTP-null background promotes very low-density lipoprotein production in mice.

Authors:  Amirfarbod Yazdanyar; Xian-Cheng Jiang
Journal:  Hepatology       Date:  2012-06-11       Impact factor: 17.425

3.  Treatment of lipid disorders in patients with diabetes.

Authors:  Helen M Colhoun; David John Betteridge
Journal:  Curr Treat Options Cardiovasc Med       Date:  2006-02

Review 4.  Cardiovascular risk in double diabetes mellitus--when two worlds collide.

Authors:  Stephen J Cleland
Journal:  Nat Rev Endocrinol       Date:  2012-04-10       Impact factor: 43.330

5.  Elevated baseline plasma phospholipid protein (PLTP) levels are an independent predictor of long-term all-cause mortality in patients with diabetes mellitus and known or suspected coronary artery disease.

Authors:  Erdal Cavusoglu; Jonathan D Marmur; Sandeep Chhabra; Mohammad R Hojjati; Sunitha Yanamadala; Vineet Chopra; Calvin Eng; Xian-Cheng Jiang
Journal:  Atherosclerosis       Date:  2015-02-16       Impact factor: 5.162

6.  Adipocyte phospholipid transfer protein and lipoprotein metabolism.

Authors:  Hui Jiang; Amirfarbod Yazdanyar; Bin Lou; Yunqin Chen; Xiaomin Zhao; Ruohan Li; Hai Hoang Bui; Ming-Shang Kuo; Mohamad Navab; Shucun Qin; Zhiqiang Li; Weijun Jin; Xian-Cheng Jiang
Journal:  Arterioscler Thromb Vasc Biol       Date:  2014-12-04       Impact factor: 8.311

7.  Genetic and nongenetic sources of variation in phospholipid transfer protein activity.

Authors:  Gail P Jarvik; Ramakrishnan Rajagopalan; Elisabeth A Rosenthal; Gertrud Wolfbauer; Laura McKinstry; Aditya Vaze; John Brunzell; Arno G Motulsky; Deborah A Nickerson; Patrick J Heagerty; Ellen M Wijsman; John J Albers
Journal:  J Lipid Res       Date:  2009-11-02       Impact factor: 5.922

Review 8.  Insulin resistance in type 1 diabetes: what is 'double diabetes' and what are the risks?

Authors:  S J Cleland; B M Fisher; H M Colhoun; N Sattar; J R Petrie
Journal:  Diabetologia       Date:  2013-04-24       Impact factor: 10.122

9.  Liver-specific phospholipid transfer protein deficiency reduces high-density lipoprotein and non-high-density lipoprotein production in mice.

Authors:  Amirfarbod Yazdanyar; Wei Quan; Weijun Jin; Xian-Cheng Jiang
Journal:  Arterioscler Thromb Vasc Biol       Date:  2013-07-11       Impact factor: 8.311

10.  Haptoglobin inhibits phospholipid transfer protein activity in hyperlipidemic human plasma.

Authors:  Ryan J Henderson; Kishor M Wasan; Carlos G Leon
Journal:  Lipids Health Dis       Date:  2009-07-23       Impact factor: 3.876

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.